Hypertension is a treatable major cardiovascular (CV) risk factor, which afflicts 30% of American adults. Despite many classes of antihypertensive drugs, control rates are poor, leading to CV events, renal failure, and stroke. The most common form of secondary hypertension is primary aldosteronism (PA), with a prevalence of 8-10% amongst all hypertensive patients and 14-30% among patients with resistant hypertension. Despite facile identification using aldosterone/renin ratio (ARR) and readily available treatment with directed therapies, screening rates for PA are extremely low (<0.1% of all hypertensives). The reasons for this missed opportunity include the long, complex, and difficult evaluation of PA. Accurate subtyping of PA into aldosterone-producing adenoma (APA, unilateral 30% of PA) or idiopathic hyperaldosteronism (IHA, bilateral, ~65% of PA) is essential to guide treatment. Surgery is recommended for most APAs and mineralocorticoid receptor antagonist (MRA) for IHA. Adrenal vein sampling (AVS) is the only test that reliably distinguishes APA from IHA, but few centers perform this technically challenging procedure well. A simple blood test to identify surgically curable cases of PA would be a major advance in the management of hypertension, particularly patients with resistant hypertension. Our basic research studies have shown that nearly all APAs express some steroidogenic enzymes not normally found in aldosterone-producing cells. Based on that finding, we then showed that unusual hybrid steroids and precursors, such as 18-hydroxycortisol (18OHF) are more abundant in serum from patients with APA than those with IHA. However, the normal adrenal makes small amounts of some of these steroids, leading to overlap and poor discrimination. By combining dynamic testing (saline or dexamethasone suppression) and steroid profiling using mass spectrometry, we will identify steroids and ratios, which reliably distinguish APA from IHA patients. This proposal will develop a clinically useful diagnostic test that will define patients who DO NOT have APAs and eliminate their need for imaging and AVS. This work will encourage screening for PA and reduce the cost and risk of the evaluation. The findings from the proposed pilot studies will be used to develop multi-center trials of the testing algorithm, which will enhance the adoption and dissemination of this approach to improve patient care and outcomes.
Primary aldosteronism (PA) has the distinction of being the most common adrenal disease as well as the most common cause of secondary hypertension. Studies of its prevalence suggest that 1 in 30 American adults have PA, but less than 1% are screened or diagnosed, largely because the evaluation is long, complicated, and expensive. The long-term goal of our research is to define novel steroid markers that would allow wider screening for PA and would rapidly distinguish patients who will benefit from a comprehensive evaluation to find a surgically curable form of PA (adrenal tumor) from those who should be treated with mineralocorticoid antagonist (MRA) therapy. This approach will conserve healthcare resources by sparing many patients expensive imaging and invasive studies, increase the use of MRA therapy, improve blood pressure control rates, and reduce the burden of hypertension-associated cardiovascular events, particularly in the patients who suffer from the greatest end-organ damage.
| Byrd, James Brian; Turcu, Adina F; Auchus, Richard J (2018) Primary Aldosteronism. Circulation 138:823-835 |
| Nanba, Aya T; Nanba, Kazutaka; Byrd, James B et al. (2017) Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. Clin Endocrinol (Oxf) 87:665-672 |
| Nanba, Kazutaka; Vaidya, Anand; Williams, Gordon H et al. (2017) Age-Related Autonomous Aldosteronism. Circulation 136:347-355 |
| Williams, Tracy A; Lenders, Jacques W M; Mulatero, Paolo et al. (2017) Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 5:689-699 |
| Poothong, Juthakorn; Sopha, Pattarawut; Kaufman, Randal J et al. (2017) IRE1? nucleotide sequence cleavage specificity in the unfolded protein response. FEBS Lett 591:406-414 |
| Jin, Jung-Kang; Blackwood, Erik A; Azizi, Khalid et al. (2017) ATF6 Decreases Myocardial Ischemia/Reperfusion Damage and Links ER Stress and Oxidative Stress Signaling Pathways in the Heart. Circ Res 120:862-875 |
| Grootjans, Joep; Kaser, Arthur; Kaufman, Randal J et al. (2016) The unfolded protein response in immunity and inflammation. Nat Rev Immunol 16:469-84 |
| Hattangady, Namita G; Karashima, Shigehiro; Yuan, Lucy et al. (2016) Mutated KCNJ5 activates the acute and chronic regulatory steps in aldosterone production. J Mol Endocrinol 57:1-11 |
| Han, Jaeseok; Kaufman, Randal J (2016) The role of ER stress in lipid metabolism and lipotoxicity. J Lipid Res 57:1329-38 |
| Mollereau, B; Rzechorzek, N M; Roussel, B D et al. (2016) Adaptive preconditioning in neurological diseases - therapeutic insights from proteostatic perturbations. Brain Res 1648:603-616 |
Showing the most recent 10 out of 15 publications
